Reportlinker Adds Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016

NEW YORK, May 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016

http://www.reportlinker.com/p0187645/Gastroesophageal-Reflux-Disease---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist's new report, "Gastroesophageal Reflux Disease (GERD) – Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global gastroesophageal reflux disease market. The report identifies the key trends shaping and driving the global gastroesophageal reflux disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global gastroesophageal reflux disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key driver and challenges of the global GERD market. Its Scope includes:

- Annualized global GERD market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.

- Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include H+/K+ ATPase Inhibitor, H2 antagonist, 5-HT4 receptor agonist, GABA-B receptor Agonist and mGluR5 antagonist.

- Analysis of the current and future market competition in the global GERD market. Key market players covered are AstraZeneca, Addex Pharmaceuticals, XenoPort and Vecta.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with GERD.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global gastro-oesophageal reflux disease market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global gastro-oesophageal reflux disease market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global gastro-oesophageal reflux disease market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 GERD Therapeutics Market: Market Characterization 6

2.1 Overview 6

2.2 GERD Therapeutics Market Size 6

2.3 GERD Therapeutics Market Forecast and CAGR 7

2.4 Drivers and Barriers for the GERD Therapeutics Market 8

2.4.1 Drivers for the GERD Therapeutics Market 8

2.4.2 Barriers for the GERD Therapeutics Market 9

2.5 Opportunity and Unmet Need 9

2.6 Key Takeaway 10

3 GERD Therapeutics Market: Competitive Assessment 11

3.1 Overview 11

3.2 Strategic Competitor Assessment 11

3.3 Product Portfolio for Major Marketed Products in the GERD Therapeutics Market 11

3.3.1 Nexium (esomeprazole) 11

3.3.2 Aciphex (rabeprazole sodium) 13

3.3.3 Prevacid (lansoprazole) 14

3.3.4 Prilosec (omeprazole) 16

3.3.5 Protonix (pantoprazole sodium) 17

3.3.6 Tagamet (cimetidine) 18

3.3.7 Pepcid (famotidine) 18

3.3.8 Zantac (ranitidine hydrochloride) 19

3.3.9 Axid (nizatidine) 19

3.4 Key Takeaway 21

4 GERD Therapeutics Market: Pipeline Assessment 22

4.1 Overview 22

4.2 Strategic Pipeline Assessment 22

4.2.1 Technology Trends Analytical Framework 22

4.3 GERD Therapeutics – Promising Drugs under Clinical Development 23

4.4 Molecule Profiles for Promising Drugs under Clinical Development 24

4.4.1 XP19986 24

4.4.2 AZD3355 25

4.4.3 ADX10059 26

4.4.4 Vecam 27

4.5 GERD Therapeutics Market - Pipeline Assessment by Mechanism of Action 27

4.6 GERD Therapeutics Market - Pipeline Assessment by Phase of Clinical Development 28

4.6.1 GERD Therapeutics – Phase III Clinical Pipeline 29

4.6.2 GERD Therapeutics – Phase II Clinical Pipeline 29

4.6.3 GERD Therapeutics – Phase I Clinical Pipeline 30

4.6.4 GERD Therapeutics – Preclinical Pipeline 30

4.6.5 Discontinued/Suspended Drugs for GERD 31

4.7 Key Takeaway 31

5 GERD Therapeutics Market: Implications for Future Market Competition 32

6 GERD Therapeutics Market: Key Players in the GERD Therapeutics Market 33

6.1 XenoPort, Inc. 33

6.1.1 Company Overview 33

6.1.2 XP19986 34

6.2 AstraZeneca 35

6.2.1 Company Overview 35

6.2.2 AZD3355 35

6.3 Addex Pharmaceuticals 36

6.3.1 Company Overview 36

6.3.2 ADX10059 37

6.4 Vecta Ltd. (Vecta) 37

6.4.1 Company Overview 37

6.4.2 Vecam 38

7 GERD Therapeutics Market: Appendix 39

7.1 Market Definition 39

7.2 Abbreviations 39

7.3 Research Methodology 40

7.4 Coverage 40

7.5 Secondary Research 41

7.6 Primary Research 41

7.7 Models 41

7.8 Forecasts 42

7.9 Expert Panels 42

7.10 GlobalData Consulting 42

7.11 Contact Us 42

7.12 Disclaimer 42

1.1 List of Tables

Table 1: GERD Therapeutics Market, Global, Revenues ($ billion), 2001-2009 7

Table 2: GERD Therapeutics Market, Global, Revenue Forecasts ($ billion), 2009-2016 8

Table 3: GERD Therapeutics Market, Global, Clinical Study Details of Nexium, 2010 13

Table 4: GERD Therapeutics Market, Global, Clinical Study Details of Aciphex, 2010 14

Table 5: Major Marketed Products Comparison in the GERD Therapeutics Market , 2010 20

Table 6: GERD Therapeutics Market, Global, Most Promising Molecules under Clinical Development, February 2010 23

Table 7: GERD Therapeutics Market, Global, Phase III Clinical Pipeline, 2010 29

Table 8: GERD Therapeutics Market, Global, Phase II Clinical Pipeline, 2010 29

Table 9: GERD Therapeutics Market, Global, Phase I Clinical Pipeline, 2010 30

Table 10: GERD Therapeutics Market, Global, Preclinical Pipeline, 2010 30

Table 11: GERD Therapeutics Market, Global, List of Discontinued Drugs for GERD, 2010 31

1.2 List of Figures

Figure 1: GERD Therapeutics Market, Global, Revenues ($ billion), 2001-2009 7

Figure 2: GERD Therapeutics Market, Global, Revenue Forecasts ($ billion), 2009-2016 8

Figure 3: Opportunity and Unmet Need in the GERD Therapeutics Market, 2010 10

Figure 4: Strategic Competitor Assessment of the Major Marketed Products in GERD Therapeutics Market, 2010 11

Figure 5: Technology Trends Analytic Framework of the GERD Therapeutics Pipeline, 2010 22

Figure 6: Technology Trends Analytic Framework of the GERD Therapeutics Pipeline- Description, 2010 23

Figure 7: GERD Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010 28

Figure 8: GERD Therapeutics Market, Global, Clinical Pipeline, 2010 28

Figure 9: Implications for Future Market Competition in the GERD Therapeutics Market, 2010 32

Figure 10: GERD Therapeutics Market, Global, Clinical Pipeline by Company, 2010 33

Figure 11: GlobalData Methodology, 2010 40

Companies Mentioned

XenoPort, Inc.

AstraZeneca

Addex Pharmaceuticals

Vecta Ltd. (Vecta)

To order this report:

Drug and Medication Industry: Gastroesophageal Reflux Disease - Drug Pipeline Analysis and Market Forecasts to 2016

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker